Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 129

1.

Eribulin mesylate, a novel microtubule inhibitor in the treatment of breast cancer.

Cortes J, Montero AJ, Glück S.

Cancer Treat Rev. 2012 Apr;38(2):143-51. doi: 10.1016/j.ctrv.2011.03.006. Epub 2011 May 8. Review.

PMID:
21550727
[PubMed - indexed for MEDLINE]
2.

A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies.

Goel S, Mita AC, Mita M, Rowinsky EK, Chu QS, Wong N, Desjardins C, Fang F, Jansen M, Shuster DE, Mani S, Takimoto CH.

Clin Cancer Res. 2009 Jun 15;15(12):4207-12. doi: 10.1158/1078-0432.CCR-08-2429. Epub 2009 Jun 9.

PMID:
19509177
[PubMed - indexed for MEDLINE]
Free Article
3.

Eribulin mesylate: a novel halichondrin B analogue for the treatment of metastatic breast cancer.

McBride A, Butler SK.

Am J Health Syst Pharm. 2012 May 1;69(9):745-55. doi: 10.2146/ajhp110237. Review.

PMID:
22517020
[PubMed - indexed for MEDLINE]
4.

Eribulin mesylate for the treatment of breast cancer.

Cigler T, Vahdat LT.

Expert Opin Pharmacother. 2010 Jun;11(9):1587-93. doi: 10.1517/14656566.2010.486790. Review.

PMID:
20450446
[PubMed - indexed for MEDLINE]
5.

Eribulin mesylate for the treatment of late-stage breast cancer.

Gourmelon C, Frenel JS, Campone M.

Expert Opin Pharmacother. 2011 Dec;12(18):2883-90. doi: 10.1517/14656566.2011.637490. Epub 2011 Nov 17. Review.

PMID:
22087618
[PubMed - indexed for MEDLINE]
6.

Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine.

Cortes J, Vahdat L, Blum JL, Twelves C, Campone M, Roché H, Bachelot T, Awada A, Paridaens R, Goncalves A, Shuster DE, Wanders J, Fang F, Gurnani R, Richmond E, Cole PE, Ashworth S, Allison MA.

J Clin Oncol. 2010 Sep 1;28(25):3922-8. doi: 10.1200/JCO.2009.25.8467. Epub 2010 Aug 2.

PMID:
20679609
[PubMed - indexed for MEDLINE]
7.

Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.

Vahdat LT, Pruitt B, Fabian CJ, Rivera RR, Smith DA, Tan-Chiu E, Wright J, Tan AR, Dacosta NA, Chuang E, Smith J, O'Shaughnessy J, Shuster DE, Meneses NL, Chandrawansa K, Fang F, Cole PE, Ashworth S, Blum JL.

J Clin Oncol. 2009 Jun 20;27(18):2954-61. doi: 10.1200/JCO.2008.17.7618. Epub 2009 Apr 6.

PMID:
19349550
[PubMed - indexed for MEDLINE]
8.

Advances in therapy: eribulin improves survival for metastatic breast cancer.

Morris PG.

Anticancer Drugs. 2010 Nov;21(10):885-9. doi: 10.1097/CAD.0b013e32833ed62e. Review.

PMID:
20838209
[PubMed - indexed for MEDLINE]
9.

Eribulin mesylate (E7389): review of efficacy and tolerability in breast, pancreatic, head and neck, and non-small cell lung cancer.

Scarpace SL.

Clin Ther. 2012 Jul;34(7):1467-73. doi: 10.1016/j.clinthera.2012.06.003. Epub 2012 Jun 25. Review.

PMID:
22739019
[PubMed - indexed for MEDLINE]
10.

Eribulin.

Perry CM.

Drugs. 2011 Jul 9;71(10):1321-31. doi: 10.2165/11207520-000000000-00000. Review.

PMID:
21770478
[PubMed - indexed for MEDLINE]
11.

Eribulin: rediscovering tubulin as an anticancer target.

Jimeno A.

Clin Cancer Res. 2009 Jun 15;15(12):3903-5. doi: 10.1158/1078-0432.CCR-09-1023. Epub 2009 Jun 9.

PMID:
19509144
[PubMed - indexed for MEDLINE]
Free Article
12.

Eribulin mesylate.

Jain S, Vahdat LT.

Clin Cancer Res. 2011 Nov 1;17(21):6615-22. doi: 10.1158/1078-0432.CCR-11-1807. Epub 2011 Aug 22. Review.

PMID:
21859830
[PubMed - indexed for MEDLINE]
Free Article
13.

Eribulin mesylate (Halaven) for breast cancer.

[No authors listed]

Med Lett Drugs Ther. 2011 Apr 18;53(1362):30-1.

PMID:
21502935
[PubMed - indexed for MEDLINE]
14.

The European medicines agency review of eribulin for the treatment of patients with locally advanced or metastatic breast cancer: summary of the scientific assessment of the committee for medicinal products for human use.

Pean E, Klaar S, Berglund EG, Salmonson T, Borregaard J, Hofland KF, Ersbøll J, Abadie E, Giuliani R, Pignatti F.

Clin Cancer Res. 2012 Sep 1;18(17):4491-7. doi: 10.1158/1078-0432.CCR-11-3075. Epub 2012 Jul 24.

PMID:
22829199
[PubMed - indexed for MEDLINE]
Free Article
15.

Effectiveness and safety of eribulin mesylate: a new therapeutic option in the treatment of metastatic breast cancer.

O'Sullivan Coyne G, Walsh J, Kelly CM.

Expert Opin Drug Saf. 2012 Jul;11(4):643-50. doi: 10.1517/14740338.2012.698608. Epub 2012 Jun 14.

PMID:
22694309
[PubMed - indexed for MEDLINE]
16.

A phase II study of the halichondrin B analog eribulin mesylate in gemcitabine refractory advanced pancreatic cancer.

Renouf DJ, Tang PA, Major P, Krzyzanowska MK, Dhesy-Thind B, Goffin JR, Hedley D, Wang L, Doyle L, Moore MJ.

Invest New Drugs. 2012 Jun;30(3):1203-7. doi: 10.1007/s10637-011-9673-x. Epub 2011 Apr 28.

PMID:
21526355
[PubMed - indexed for MEDLINE]
17.

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.

Cortes J, O'Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, Chollet P, Manikas A, Diéras V, Delozier T, Vladimirov V, Cardoso F, Koh H, Bougnoux P, Dutcus CE, Seegobin S, Mir D, Meneses N, Wanders J, Twelves C; EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician's Choice Versus E7389) investigators.

Lancet. 2011 Mar 12;377(9769):914-23. doi: 10.1016/S0140-6736(11)60070-6. Epub 2011 Mar 2.

PMID:
21376385
[PubMed - indexed for MEDLINE]
18.

The place for eribulin in the treatment of metastatic breast cancer.

Gradishar WJ.

Curr Oncol Rep. 2011 Feb;13(1):11-6. doi: 10.1007/s11912-010-0145-9. Review.

PMID:
21104168
[PubMed - indexed for MEDLINE]
19.

Eribulin: a novel cytotoxic chemotherapy agent.

Preston JN, Trivedi MV.

Ann Pharmacother. 2012 Jun;46(6):802-11. doi: 10.1345/aph.1Q636. Epub 2012 May 22. Review.

PMID:
22619477
[PubMed - indexed for MEDLINE]
20.

[Clinical evaluation of eribulin mesylate for the treatment of metastatic breast cancer].

Matsuzaki H, Tohnosu N, Yoshiwara C, Maruyama T, Tanaka H, Natsume T, Miyazaki A, Sato Y, Ohta T, Yamamoto Y, Aikawa M, Ohtsuka R, Yanagihara A, Iwata K, Shiratori T, Miyazawa Y.

Gan To Kagaku Ryoho. 2014 Apr;41(4):455-9. Japanese.

PMID:
24743360
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk